Arrowhead Pharmaceuticals Inc

2 lis 2026, 22:01 UTC

Arrowhead Pharmaceuticals, Inc. is trading modestly higher during after-market hours, reflecting the broader market's gains following positive economic data for October.

30 paź 2026, 20:41 UTC

Arrowhead Pharmaceuticals, Inc. shares declined during after-market hours on Friday, breaking a trend of higher daily closes observed in recent sessions.

29 paź 2026, 23:26 UTC

Arrowhead Pharmaceuticals, Inc. is trading lower in after-market hours, continuing a downward trend since Thursday's close and reaching its lowest point of the session.

28 paź 2026, 19:46 UTC

Arrowhead Pharmaceuticals, Inc. is trading higher in Wednesday's market session, reaching a peak return that reflects routine performance for this time of day.

27 paź 2026, 20:13 UTC

Arrowhead Pharmaceuticals, Inc. is trading modestly higher in after-market hours, reflecting unusual strength.

26 paź 2026, 22:21 UTC

Arrowhead Pharmaceuticals Inc is trading lower in after-market hours, having declined from a brief return to even since Monday's close.

23 paź 2026, 20:13 UTC

Arrowhead Pharmaceuticals Inc shares are trading lower in after-hours action, continuing a decline observed over the past three sessions and remaining below its 20-day moving average.

22 paź 2026, 20:07 UTC

Arrowhead Pharmaceuticals Inc shares are declining, pulling back from an earlier high and trading near the lower end of their one-month range.

21 paź 2026, 20:07 UTC

Arrowhead Pharmaceuticals' stock declined after reporting interim data from a Phase 1/2a trial for ARO-MAPT, despite promising early results in targeting Alzheimer's disease.

20 paź 2026, 20:08 UTC

Arrowhead Pharmaceuticals Inc shares advanced during Tuesday's trading session, experiencing a notable early spike before retracing slightly but ultimately closing higher.

16 paź 2026, 20:07 UTC

Arrowhead Pharmaceuticals shares are declining, with UBS setting a price target of $109 and HC Wainwright at $120 amid concerns over stock performance.

15 paź 2026, 19:16 UTC

Arrowhead Pharmaceuticals shares are declining despite UBS maintaining a Buy rating with a price target of $109 and H.C. Wainwright setting a higher target of $120.

14 paź 2026, 22:06 UTC

Arrowhead Pharmaceuticals reports interim results from a Phase 1/2a study of ARO-MAPT for Alzheimer's treatment, with shares advancing in after-market trading.

13 paź 2026, 22:02 UTC

Arrowhead Pharmaceuticals Inc shares advanced during after-market hours, gaining ground amid caution from social media users ahead of an important call with a key opinion leader.

12 paź 2026, 22:26 UTC

Arrowhead Pharmaceuticals Inc's shares were roughly flat in after-market trading, significantly below their 20-day moving average after a substantial decline over the past month.

9 paź 2026, 20:12 UTC

Arrowhead Pharmaceuticals Inc shares declined in after-market trading, remaining significantly below its 20-day moving average and near the lower end of its one-month range.

8 paź 2026, 20:07 UTC

Arrowhead Pharmaceuticals announces FDA entry of plozasiran into the Split Real Time Application Review pilot program, despite ongoing declines in its stock price.

6 paź 2026, 20:00 UTC

Arrowhead Pharmaceuticals Inc shares fell sharply, trading at 62, marking the fifth consecutive session of lower closes and remaining significantly below its 20-day moving average.

5 paź 2026, 21:20 UTC

Arrowhead Pharmaceuticals Inc shares are advancing in after-market trading, recovering from an earlier dip to reach their highest point of the day amid increased social media attention.

3 paź 2026, 00:00 UTC

Arrowhead Pharmaceuticals Inc has advanced in after-market trading, recovering from an initial dip and marking a notable recovery since Friday's close.

2 paź 2026, 20:07 UTC

Arrowhead Pharmaceuticals Inc shares fell modestly, continuing a downward trend with three consecutive sessions finishing lower amid a broader market decline.

1 paź 2026, 20:07 UTC

Arrowhead Pharmaceuticals Inc shares fell sharply, continuing a decline since Wednesday's close and remaining well below the 20-day moving average.

30 wrz 2026, 20:07 UTC

Arrowhead Pharmaceuticals Inc shares fell sharply as the company announced an R&D webinar on ARO-MAPT, closing near the lower end of its one-month range.

29 wrz 2026, 21:20 UTC

Arrowhead Pharmaceuticals Inc. has announced a research and development webinar on ARO-MAPT, with the stock moving higher in after-market trading.

28 wrz 2026, 19:55 UTC

Arrowhead Pharmaceuticals Inc shares fell sharply, continuing a downward trend with four consecutive sessions of losses and trading below the 20-day moving average.

26 wrz 2026, 00:01 UTC

Arrowhead Pharmaceuticals Inc is trading modestly lower in after-market hours, marking its lowest cumulative return since Friday and extending five consecutive sessions of declines.

24 wrz 2026, 19:46 UTC

Arrowhead Pharmaceuticals shares fell sharply as Goldman Sachs resumed coverage with a Neutral rating and a price target of $74 amid mixed fiscal results.

23 wrz 2026, 23:56 UTC

Arrowhead Pharmaceuticals Inc saw a modest decline in after-market trading, remaining significantly below its 20-day moving average and near the lower end of its one-month range.

22 wrz 2026, 20:06 UTC

Arrowhead Pharmaceuticals Inc is higher in Tuesday's trading, having gained notably from Monday's close, despite pulling back from a mid-afternoon peak.

21 wrz 2026, 23:25 UTC

Arrowhead Pharmaceuticals Inc declined in after-market trading, moving lower from Monday's close and remaining near the lower end of its one-month trading range.